Ask AI
EU Focused MCL TRAE IDST
Interactive EU-Focused Tool to Guide the Management of BTK Inhibitor–Related Adverse Events in MCL

Released: June 25, 2025

Expiration: December 24, 2025

About This Tool & Disclaimer

Interactive EU-Focused Tool to Guide the Management of BTK Inhibitor–Related Adverse Events in MCL

Clinical Care Options, LLC, is grateful to Georg Hess, MD, and Carlo Visco, MD, who provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

Note: The current tool was created in June 2025 and reflects the guidelines available at that time.

The goal of the tool is to educate healthcare professionals in optimizing the selection of BTK inhibitor therapy and mitigating BTK inhibitor–related toxicities to extend the duration of treatment and maximize treatment outcomes in the care of patients with mantle cell lymphoma who are receiving BTK inhibitor–based treatments.

A series of questions allows you to select individual patient characteristics that are necessary to consider when making management choices. These characteristics include whether BTK inhibitor therapy has been initiated, which BTK inhibitor is being used, whether an AE is present or an invasive procedure is planned, and the type and severity of the AE if present.

It should be noted that these are not exclusive characteristics when managing AEs in patients with mantle cell lymphoma who are receiving BTK inhibitor therapy. Other considerations that are not included in this tool, such as the presence of various comorbidities and any concurrent medications, should also be considered, when appropriate.

This tool assumes that the patient is an adult diagnosed with mantle cell lymphoma who is considering or has already started BTK inhibitor therapy.

Based on the characteristics entered, the tool will display expert-based recommendations for that specific patient case.

© 2025 Clinical Care Options, LLC. All rights reserved.

Access to and use of this Interactive Decision Support Tool titled, “Interactive EU-Focused Tool to Guide the Management of BTK Inhibitor–Related Adverse Events in MCL” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal management choices in monitoring and managing adverse events that can occur in patients with mantle cell lymphoma treated with BTK inhibitor therapy with expert guidance from Georg Hess, MD, and Carlo Visco, MD.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States FDA and/or the European Medicines Agency (EMA). A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Interactive EU-Focused Tool to Guide the Management of BTK Inhibitor–Related Adverse Events in MCL” has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2025 Clinical Care Options, LLC. All rights reserved.

Program Content